Background/Aim: The Coronavirus-19 (COVID-19) pandemic disrupted all planned, elective surgical procedures and appointment-based health services due to the decreased capacity of hospitals, healthcare professionals' focus on fighting the pandemic and efforts to protect patients, society and healthcare workers from the pandemic. The purpose of this study was to ascertain the perspective of patients on elective surgery, who applied to neurosurgery outpatient clinics at two different centers as clean and nonclean hospitals. Methods: This cross-sectional prospective study was performed between March 2021 and July 2021, during the COVID-19 pandemic. 160 patients who were offered elective surgery for various indications in neurosurgery outpatient clinics were enrolled in the study. To this end, a questionnaire was administered to patients that included information about their demographics, pandemic processes and their anxiety levels during this process. Age, level of education, COVID-19 infection and vaccination status were all questioned in the survey. Univariate and multivariate analysis were used to determine the factors that might influence a patient's decision towards surgery. Results: In the univariate analysis of the factors, educational status, pandemic-induced anxiety and whether the hospital is a pandemic hospital or not were identified as statistically significant effective factors in patients' decision to accept surgery (P<0.05).
Conclusion:We observed that the acceptance rate of patients for elective neurosurgical operations decreased during the pandemic period, but this situation was less felt in clean hospitals. We think that separating hospitals into two parts of clean and non-clean hospital is a beneficial health policy for the continuation of elective treatment procedures.
Introduction: The co-existence of primary intracranial tumors originating from different cell types is rare. While the association of meningioma and glioma is frequently reported in the literature, the number of cases with meningiomas and epidermoid cysts is relatively low. We report a unique case because the association of supra-sellar meningioma and the epidermoid cyst has not been reported before in the literature.
Case Presentation: A 50-year-old female presented to the clinic with a headache and progressive vision loss. In cranial Magnetic Resonance (MR) images, a T1A hypointense, T2A iso-hyper intense heterogenous contrasting suprasellar mass lesion was observed. The patient was operated on with a diagnosis of suprasellar meningioma. At the suprasellar region, a mass that macroscopic view and consistency compatible with epidermoid cyst ex-plored intraoperative incidentally. Two different pathological specimens were sent to pathology. The patient's pathology was reported as WHO 2021, Transitional type grade 1 Meningioma, and Epidermoid cyst content.
Conclusion: The number of cases with meningiomas and epidermoid cysts is very low in the literature. Despite advanced MR imaging techniques, cystic lesions can be overlooked in the diagnosis. The occurrence of two different histopathological types of tumors in the same localization can be explained by the local paracrine effects of the tumors.
Ochronosis is the black discoloration of connective tissues seen with alkaptonuria, a metabolic disorder. Alkaptonuria is a rare autosomal recessive metabolic disorder caused by the lack of homogentisic acid oxidase enzyme. Alkaptonuria causes degenerative changes in cartilage, intervertebral disc and other tissues. The patients operated due to lumbar disc herniation in alkatonuria are very few. In this article a case of ochronosis in which the patient was determined after lumbar discectomy is presented.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.